Singapore markets open in 7 hours 4 minutes

Molecular Templates, Inc. (MTEM)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
5.17+0.02 (+0.39%)
As of 12:12PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close5.15
Open4.90
Bid4.76 x 1000
Ask5.17 x 800
Day's range4.75 - 5.17
52-week range4.56 - 9.60
Volume3,730
Avg. volume8,195
Market cap27.785M
Beta (5Y monthly)1.32
PE ratio (TTM)N/A
EPS (TTM)-6.92
Earnings date13 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est16.50
  • GlobeNewswire

    Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update

    MT-6402 Dose Escalation (Part A) Head & Neck Patients (N=8) AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the th

  • GlobeNewswire

    Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

    AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors. The Phase 1 study is a multi-center open-lab

  • GlobeNewswire

    Molecular Templates to Participate in Upcoming Investor Conferences

    AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced participation in the following upcoming investor conferences: UBS Biopharma Conference 2023 Format: One-on-One